Literature DB >> 27154401

New migraine therapies promise prevention: A new generation of drugs could avert migraine attacks rather than merely relieve symptoms.

Philip Hunter1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27154401      PMCID: PMC5278615          DOI: 10.15252/embr.201642519

Source DB:  PubMed          Journal:  EMBO Rep        ISSN: 1469-221X            Impact factor:   8.807


× No keyword cloud information.
  8 in total

1.  Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study.

Authors:  Marcelo E Bigal; Lars Edvinsson; Alan M Rapoport; Richard B Lipton; Egilius L H Spierings; Hans-Christoph Diener; Rami Burstein; Pippa S Loupe; Yuju Ma; Ronghua Yang; Stephen D Silberstein
Journal:  Lancet Neurol       Date:  2015-09-30       Impact factor: 44.182

Review 2.  5-HT1F receptor agonists in acute migraine treatment: a hypothesis.

Authors:  N M Ramadan; V Skljarevski; L A Phebus; K W Johnson
Journal:  Cephalalgia       Date:  2003-10       Impact factor: 6.292

Review 3.  The prevalence, impact, and treatment of migraine and severe headaches in the United States: a review of statistics from national surveillance studies.

Authors:  Todd A Smitherman; Rebecca Burch; Huma Sheikh; Elizabeth Loder
Journal:  Headache       Date:  2013-03-07       Impact factor: 5.887

4.  Magnetic resonance angiography of intracranial and extracranial arteries in patients with spontaneous migraine without aura: a cross-sectional study.

Authors:  Faisal Mohammad Amin; Mohammad Sohail Asghar; Anders Hougaard; Adam Espe Hansen; Vibeke Andrée Larsen; Patrick J H de Koning; Henrik B W Larsson; Jes Olesen; Messoud Ashina
Journal:  Lancet Neurol       Date:  2013-04-09       Impact factor: 44.182

5.  Calcitonin gene-related peptide is a potent vasodilator.

Authors:  S D Brain; T J Williams; J R Tippins; H R Morris; I MacIntyre
Journal:  Nature       Date:  1985 Jan 3-9       Impact factor: 49.962

6.  Vasoconstriction in human isolated middle meningeal arteries: determining the contribution of 5-HT1B- and 5-HT1F-receptor activation.

Authors:  Z Razzaque; M A Heald; J D Pickard; L Maskell; M S Beer; R G Hill; J Longmore
Journal:  Br J Clin Pharmacol       Date:  1999-01       Impact factor: 4.335

7.  Genome-wide meta-analysis identifies new susceptibility loci for migraine.

Authors:  Verneri Anttila; Bendik S Winsvold; Padhraig Gormley; Tobias Kurth; Francesco Bettella; George McMahon; Mikko Kallela; Rainer Malik; Boukje de Vries; Gisela Terwindt; Sarah E Medland; Unda Todt; Wendy L McArdle; Lydia Quaye; Markku Koiranen; M Arfan Ikram; Terho Lehtimäki; Anine H Stam; Lannie Ligthart; Juho Wedenoja; Ian Dunham; Benjamin M Neale; Priit Palta; Eija Hamalainen; Markus Schürks; Lynda M Rose; Julie E Buring; Paul M Ridker; Stacy Steinberg; Hreinn Stefansson; Finnbogi Jakobsson; Debbie A Lawlor; David M Evans; Susan M Ring; Markus Färkkilä; Ville Artto; Mari A Kaunisto; Tobias Freilinger; Jean Schoenen; Rune R Frants; Nadine Pelzer; Claudia M Weller; Ronald Zielman; Andrew C Heath; Pamela A F Madden; Grant W Montgomery; Nicholas G Martin; Guntram Borck; Hartmut Göbel; Axel Heinze; Katja Heinze-Kuhn; Frances M K Williams; Anna-Liisa Hartikainen; Anneli Pouta; Joyce van den Ende; Andre G Uitterlinden; Albert Hofman; Najaf Amin; Jouke-Jan Hottenga; Jacqueline M Vink; Kauko Heikkilä; Michael Alexander; Bertram Muller-Myhsok; Stefan Schreiber; Thomas Meitinger; Heinz Erich Wichmann; Arpo Aromaa; Johan G Eriksson; Bryan Traynor; Daniah Trabzuni; Elizabeth Rossin; Kasper Lage; Suzanne B R Jacobs; J Raphael Gibbs; Ewan Birney; Jaakko Kaprio; Brenda W Penninx; Dorret I Boomsma; Cornelia van Duijn; Olli Raitakari; Marjo-Riitta Jarvelin; John-Anker Zwart; Lynn Cherkas; David P Strachan; Christian Kubisch; Michel D Ferrari; Arn M J M van den Maagdenberg; Martin Dichgans; Maija Wessman; George Davey Smith; Kari Stefansson; Mark J Daly; Dale R Nyholt; Daniel Chasman; Aarno Palotie
Journal:  Nat Genet       Date:  2013-06-23       Impact factor: 38.330

Review 8.  Serotonin and CGRP in migraine.

Authors:  Milan Aggarwal; Veena Puri; Sanjeev Puri
Journal:  Ann Neurosci       Date:  2012-04
  8 in total
  2 in total

1.  Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine.

Authors:  Maurice T Driessen; Joshua M Cohen; Stephen F Thompson; Oscar Patterson-Lomba; Michael J Seminerio; Karen Carr; Todor I Totev; Rochelle Sun; Erica Yim; Fan Mu; Rajeev Ayyagari
Journal:  J Headache Pain       Date:  2022-05-16       Impact factor: 8.588

2.  Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes of migraine-preventive medications in the phase 3b FOCUS study.

Authors:  Egilius L H Spierings; Xiaoping Ning; Verena Ramirez Campos; Joshua M Cohen; Steve Barash; Dawn C Buse
Journal:  Headache       Date:  2021-08-10       Impact factor: 5.887

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.